MedTrace Logo

A Training Set for the HRD Model in EOC

NCT04651933 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2020-12-04

No results posted yet for this study

Summary

A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH) is little explored in epithelial ovarian cancer (EOC) patients. This study would recruit 200 Chinese EOC patients with known BRCA1/2 mutation status and resistance to platinum-based chemotherapy. A LOH-HRD model is to be constructed based on the genetic testing in these patients. The mutated genes, HRD score model and their relationship with the prognosis, would provide a full description of for the Chinese EOC patients, and a potential explanation of platinum-resistance in such population.

Conditions

  • Epithelial Ovarian Cancer
  • BRCA Mutation
  • Loss of Heterozygosity
  • Prognosis
  • Platinum Resistance
  • Homologous Recombination Deficiency

Interventions

GENETIC

Homologous recombination deficiency model

A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH)

Sponsors & Collaborators

  • Lei Li

    lead OTHER

Principal Investigators

  • Lei Li, M.D. · Peking Union Medical College Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-26
Primary Completion
2022-11-26
Completion
2022-11-26

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04651933 on ClinicalTrials.gov